President Trump’s executive order suspending federal funding for gain-of-function research not only contains questionable assertions, but it also frames the targeted research so broadly that it is likely to affect even lower-risk infectious disease research.
Related Posts
Embracing AI Organization-Wide: Insights from Theragenics
How can an established healthcare leader harness AI to drive innovation, growth, and lasting competitive advantage? In this episode, Stewart Gandolf sits down with Michael […]
How private equity harms community hospitals
Early in the pandemic, we began using yellow cloth isolation gowns, environmentally superior, perhaps, to the paper gowns that preceded them, but not without complications. […]
Maximizing Healthcare M&A Success With Strategic Marketing
How can healthcare companies use marketing and branding to drive growth and reduce risks in preparation for mergers and acquisitions (M&A)? In this podcast, Victora […]